TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04919642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet, administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet, administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet, administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet, administered orally once daily
Study: NCT05989906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Description: Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Description: Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Description: Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Ergometer (ERGO)
Description: Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Ergometer (ERGO)
Description: Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
Study: NCT05500209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal resources' enhancement: self-efficacy
Description: Participants in this condition are asked to take part in a 7-day psychological intervention delivered through Facebook Messenger chat-bot. Each day one CBT-framed exercise aimed at coping self-efficacy enhancement is delivered. An exercise takes form 5 to 30 minutes to complete.
Study: NCT04875546

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Adolescent will receive a brief smoking cessation intervention based on the '5A' and '5R' models. Then the research assistant will ask about their tobacco use and assist them to quit using the STAR method. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Intervention
Description: In addition to the brief smoking cessation intervention based on the '5A' and '5R' models, the participants will receive brief advice on alcohol use based on the FRAMES model. Then the RA will invite participants to complete the Alcohol Use Disorders Identification Test and provide personalized feedback. There will be a one to one, 20-30 minutes semi-structured interviews with 30 participants. Participants with high(N=15) and low (N=15) adherence will be purposively selected. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The adolescents will receive the leaflets for smoking cessation and alcohol abstinence. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
Study: NCT05914142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy
Description: Radiation: Proton Therapy System (ProBeam)
Study: NCT05379348

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
Study: NCT05023096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
Study: NCT06496815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib will be taken orally twice a day, 0.2g each time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy
Description: Eligible subjects will receive transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy as previous (if have).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1,PD-L1
Description: PD-1/PD-L1 will be used as previous (if have).
Study: NCT05063227

Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: analgesia monitoring indices and changes in heart rate
Description: After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be \< 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
Study: NCT05169151

Intervention type: OTHER
Intervention: Smartphone Application
Description: Utilize smartphone application
Study: NCT04936360

Intervention type: OTHER
Intervention: questionnaires for clinical assessments
Description: questionnaires for clinical assessments

Intervention type: OTHER
Intervention: questionnaires for clinical assessments
Description: questionnaires for clinical assessments
Study: NCT05269485

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose fractionated radiotherapy
Description: Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose fractionated radiotherapy
Description: Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
Study: NCT00105651

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combined nursing invention
Study: NCT04558866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
Study: NCT06141369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: individualized mRNA neoantigen vaccine (mRNA-0523-L001)
Description: Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
Study: NCT06039124

Intervention type: OTHER
Intervention: bevacizumab treatment
Description: Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
Study: NCT06177964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lerapolturev
Description: Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lerapolturev
Description: Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine Pill
Description: Lomustine will be given as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
Study: NCT06068270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-ostoperforations (MOPs)
Description: 3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
Study: NCT06094634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Brief Alcohol Intervention (BAI): Behavioral
Description: The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and comprises 2 in-person face-to-face sessions and 2 booster telephone sessions by a trained counselor.
Study: NCT06306625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of four cycles of a 5-min brachial cuff inflation at 200 mmHg followed by a 5-min of cuff deflation, and is started as soon as possible after randomization. The intervention is repeated 12 and 24 hours after inclusion.

Intervention type: DEVICE
Group type: OTHER
Intervention: No remote ischemic conditioning
Description: A brachial cuff is positioned around the arm of the patient and no inflation or deflation is performed.
Study: NCT05497596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D (2000IU/day) for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04729673

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine
Study: NCT05068570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARMEROMTERY
Description: ARMERGOMTERY TRAINING FOR UPPERLIMB
Study: NCT05214859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Dyadic Expressive Arts Group Therapy
Description: This therapy utilizes different art modalities, such as visual art, music, movement, dance, drama, and writing, as therapeutic means. With multiple sensory stimulations from different art forms, the therapy facilitates communication, expression, perception, and interactions. The therapy consists of 8 weekly 90 minutes sessions, with 3-4 mother-child dyads in each therapy group. Each session will follow the basic structure of Expressive Arts Therapy, including check-in, warm-up, core art-making, sharing, and closure. The following themes related to the mother-child relationship will be included, such as communication, relationship, expression, empathy, interaction, love, gratitude, and connection.
Study: NCT05873998

Intervention type: DIAGNOSTIC_TEST
Intervention: Slow pressure-volume curve
Description: Patients will be sequentially subjected to a slow pressure-volume curve and a lung recruitment maneuver
Study: NCT04661709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wen Xin granule
Description: one dose daily, two times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin Calcium
Description: 20 mg tablet, one tablet each night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: 20 mg tablet, one tablet each night.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: one tablet， twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: one tablet， twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg, two times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg, two times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WXG placebo
Description: one dose daily, two times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glyceryl trinitrate
Description: be taken when angina pectoris attacks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyceryl trinitrate
Description: be taken when angina pectoris attacks.
Study: NCT05909982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy combined with ischemic post-conditioning
Description: Ischemic post-conditioning will be applied after successful recanalization of the culprit artery by thrombectomy. Ischemic post-conditioning consists of briefly repeated four cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
Study: NCT04262687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m²/day, from day 1 to 14 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by IV infusion over 30 minutes, on day 1 of each cycle
Study: NCT04944511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
Study: NCT04639973

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Group 1 (First trimester ultrasound)
Description: A detailed first trimester anatomy ultrasound will be performed,at the visit when the subject is confirmed to be of eligible gestational age. After this detailed research ultrasound, which will be limited to 15 minutes, subject will then receive the clinically indicated dating ultrasound or nuchal translucency measurement. The patient will complete a survey about her satisfaction with this technique via email.as a safety measure, if an anomaly is suspected on the day of the detailed first trimester anatomy scan, the patient will be unblinded. Patients in this arm are later scheduled for a second trimester ultrasound by the clinical team, as this is part of standard obstetrical care.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 (Second trimester anatomy ultrasound)
Description: Patients do not undergo a detailed first trimester ultrasound , but will receive the clinically indicated limited ultrasound for dating or for nuchal translucency. Patient will then undergoes a second trimester ultrasound by the clinical team as part of standard obstetrical care and completes a survey regarding her satisfaction with this technique via email.
Study: NCT05744089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCA pump
Description: simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
Study: NCT05073614

Intervention type: GENETIC
Group type: OTHER
Intervention: immunohistochemical detection of Heparanase in chronic gastritis
Description: immunohistochemical detection of Heparanase in chronic gastritis specimens.
Study: NCT05435651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multitask game-based digital therapy
Description: To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Schulte Grid digital game
Description: To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
Study: NCT06047340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G:DATA, dementia screen videogame
Description: A videogame for screening

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G:DATA, dementia screen videogame
Description: A videogame for screening

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G:DATA, dementia screen videogame
Description: A videogame for screening
Study: NCT04911036

Intervention type: OTHER
Intervention: Questionnaires
Description: Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
Study: NCT05639127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Nebulization of prednisolone
Study: NCT05143892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag administered at the described frequency to achieve a target platelet count

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Supportive care other than TPO-RAs or recombinant human thrombopoietin.
Study: NCT06490458

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance exercises and cardiac rehabilitation (intervention) for patients for 7 Days, 3 times/week for duration of 25-30 min/ session.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance exercises and cardiac rehabilitation (intervention) for patients for 7 Days, 3 times/week for duration of 25-30 min/ session.
Study: NCT06469996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Description: Connective Tissue Massage will be applied by an experienced physiotherapist for a total of 12 sessions 2 days a week for 6 weeks. While the patients are in sitting position, starting from the lumbosacral region, the lower thoracic, scapular, interscapular and cervical regions will be included in the treatment respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self myofascial relaxation
Description: Self myofascial relaxation will be practiced with foam roller in patients with Fibromyalgia.
Study: NCT05601648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin (25mg tablet) plus supportive psychotherapy
Study: NCT06468397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSeelr™
Description: The iSeelr™ device will be used to deliver 1940nm laser output along with low airflow to seal a retinal tear
Study: NCT06414811

Intervention type: OTHER
Intervention: HYPOTENSİON
Description: MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.